Eltrog 25mg Tablet
Prescription Required
Marketed By
glenmark
Pack of
7 Tablets in Strip
Salt Composition
Eltrombopag Olamine
Storage
Keep in cold place
₹550₹750
26.67% Off
Inclusive of all taxes
1
Eltrog 25mg Tablet
Delivering To: —
All Substitutes
Indication
Hepatitis C, Hepatitis Medicines, Low Red Platelet Count
Description
Eltrog 25mg Tablet is prescribed by the doctor to treat low platelet counts in specific blood-related conditions. It is mainly given in combination with other medicines to treat a particular condition or increase effectiveness. Eltrog 25mg Tablet contains Eltrombopag Olamine that promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia.
Common Side Effects
Eltrog 25mg Tablet can cause multiple side effects, most of which are mild to moderate and often temporary. Patients are advised to inform their healthcare provider immediately if symptoms stays for prolonged period of time.
● Headache
● Nausea
● Tiredness
● Diarrhea
● Insomnia
● Dizziness
● Loss of Appetite
● Rashes
● Muscle Pain
● Fever
● Chills
● Allergic Reaction
● Liver Problem
● Blood Clots
● Allergic Reaction
Dosage And Administration
The usual dose of Eltrog 25mg Tablet is one tablet daily. It should be taken on an empty stomach, at the same time each day for consistent blood levels. Consult your doctor for individual dosage as it may vary person to person based on its stage and overall health.Tablet is taken orally with the help of water. Avoid breaking, chewing, biting and crushing of tablet to maintain the medication efficacy.
Mechanism Of Action
Eltrog 25mg Tablet contains 25mg of Eltrombopag Olamine, Eltrombopag binds to and activates the transmembrane domain of the TPO receptor (c-Mpl) on megakaryocyte progenitors in the bone marrow, triggering signaling pathways. This promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet formation and reduced bleeding risk in conditions like chronic ITP, hepatitis C-related thrombocytopenia, or severe aplastic anemia.
Safety Advice
Alcohol
unsafe
It is strongly advised to avoid or limit alcohol consumption during Eltrog 25mg Tablet. It can worsen the liver and kidney damage. Consult your doctor for more information on this.
Driving
caution
It is advisable not to drive or operate any heavy machinery, as you may feel dizzy after taking Eltrog 25mg Tablet.
Pregnancy
unsafe
Eltrog 25mg Tablet is considered unsafe for pregnancy due to fetal harm. Please consult your doctor in such condition.
Breast Feeding
consult your doctor
Breast Feeding is also not advisable during Eltrog 25mg Tablet course. Consult your Doctor for more information.
Kidney
caution
Share your medical history related to kidney cancer or infection with your doctor before taking Eltrog 25mg Tablet. As this medication can cause potential harm to kidney.
Liver
caution
Notify your doctor about any liver disease or infection before starting Eltrog 25mg Tablet course. As this medication can cause potential liver damage.
Faqs
Eltrog 25mg Tablet is used to treat low platelet counts in specific blood-related conditions.
Yes, Eltrog 25mg Tablet can be given in combination with other medicine based on doctor's assessment about your disease and its stage.Consult the doctor about drug interaction.
Take the Eltrog 25mg Tablet as soon as you remember it unless its near the time of next dose. Avoid over dosage of medicine as it can cause harm to the body.
Eltrog 25mg Tablet medication course usually varies, depending on the viral genotype and patient factors.
Yes,Eltrog 25mg Tablet negatively effect the kidney as well as liver of the body to a great extent if not monitored timely.
References
• Garnock-Jones, K. P., & Keam, S. J. (2009). Eltrombopag. Drugs, 69(5), 567-576.
• Gonzalez-Porras, J. R., & Bastida, J. M. (2018). Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Therapeutic advances in drug safety, 9(6), 263-285.
• Lozano, M. L., Segú-Vergés, C., Coma, M., Álvarez-Roman, M. T., González-Porras, J. R., Gutiérrez, L., ... & Butta, N. (2021). Elucidating the mechanism of action of the attributed immunomodulatory role of eltrombopag in primary immune thrombocytopenia: an in silico approach. International journal of molecular sciences, 22(13), 6907.
• Raslova, H., Vainchenker, W., & Plo, I. (2016). Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica, 101(12), 1443.
Related Products
MARKETER DETAILS
glenmark
DISCLAIMER
The contents of this website are for informative purposes only. They are not deliberated to be an alternative to any professional medical prescription and treatment. Seek the advice of a qualified health provider for questions regarding the medical condition. Do not ignore any professional medical advice because of something you have read on this website. This website offers links to other websites, thereby enabling you to go to the other website directly. Therefore, Magicine Pharma isn't responsible for the content of the links in the website or links in the linked websites. The links are provided to assist the visitors and are not approved by any professional health provider.